|
|
|
Taglich's Company Profile
for: |
www.cardiumthx.com
|
Cardium Therapeutics, Inc. |
Symbol:
CXM
Analyst:
Juan Noble
Taglich Rating:
Speculative Buy
Price Target:
$4.00
Time Horizon:
12 Months
Rating Established:
October 19, 2007
Price When Established:
$3.00
Most Recent Report:
May 12, 2008
Price When Issued:
$2.19
|
|
|
Most Recent Update |
|
Updated
Earnings Note (Dated May 12, 2008) |
|
What's New |
|
New information will be posted soon... |
|
Company Description |
Cardium Therapeutics, Inc., headquartered in San Diego, CA, is a biomedical company that is developing regenerative therapies for the treatment of myocardial ischemia and diabetic foot ulcers. The company’s surface and endovascular temperature modulation systems, which are already commercialized, have applications in neurosurgery, cardiac arrest, stroke and central nervous system trauma cases.
The company is developing or commercializing potentially wide selling products with a view to offering them for acquisition to large pharmaceutical or biomedical firms. The lead pipeline product, Generx, aims to reverse microvascular ischemia by promoting angiogenesis. A second pipeline product, Excellarate, is a wound care product developed to heal diabetic foot ulcers that are not responsive to standard treatments. Temperature modulation systems, a product line already commercialized, consists of both endovascular and external cooling systems helpful in treating neurosurgery, cardiac arrest, stroke and central nervous system trauma patients. |
|
Taglich Research Reports |
Updated
Research Report (Dated April 15, 2008)
Updated
Earnings Note (Dated March 17, 2008)
Updated
Research Report (Dated December 13, 2007)
Updated
Earnings Note (Dated November 15, 2007)
Initial Research Report (Dated October
19, 2007)
All Research Reports are in Adobe Acrobat format.
(for the latest Adobe Acrobat reader click
here)
*The information and statistical data
contained herein have been obtained from sources, which we
believe to be reliable but in no way are warranted by us as to
accuracy or completeness. We do not undertake to advise you as
to changes in figures or our views. This is not a solicitation
of any order to buy or sell. Taglich Brothers, Inc. is fully
disclosed with its clearing firm, Pershing, LLC, is not a market
maker and does not sell to or buy from customers on a principal
basis. The above statements are the opinion of Taglich Brothers,
Inc. and are not a guarantee that the target price for the stock
will be met or that predicted business results for the company
will occur. There may be instances when fundamental, technical
and quantitative opinions contained in the reports are not in
concert. We, our affiliates, any officer, director or
stockholder or any member of their families may from time to
time purchase or sell any of the above-mentioned or related
securities. Analysts and members of the Research Department are
prohibited from buying or selling securities issued by the
companies that Taglich Brothers, Inc. has a research
relationship with, except if ownership of such securities was
prior to the start of such relationship, then an Analyst or
member of the Research Department may sell such securities after
obtaining expressed written permission from the Director of
Research. As of the date of this report, no officers or
employees of Taglich Brothers, Inc. owned any of the company’s
shares. All research issued by Taglich Brothers, Inc. is based
on public information. Taglich Brothers, Inc. does not currently
have an Investment Banking relationship with the company
mentioned and was not a manager or co-manager of any offering
for the company within the last three years. The company paid a
$5,000 (USD) engagement fee in August, 2007 and will, commencing
upon distribution of our initial report, pay $1,750 (USD) per
month for the creation and dissemination of research reports.
For further information and Taglich Brothers, Inc. ownership
data please refer to each individual report. |
|
Send this Page to a friend |
|
To send this page to a friend, just fill out the form below and press
the "send it" button!
|
|
|
Taglich Covered Companies |
AeroCentury Corp.
Anglo Swiss Resources, Inc.
Avensys Corporation
BioForce Nanosci. Holdings, Inc.
Caneum Inc.
Cardium Therapeutics, Inc.
China 3C Group
Command Security Corp.
CTI Industries Corp
Derma Sciences, Inc.
DRI Corporation
EnerLume Energy Mgt. Corp.
EP MedSystems, Inc.
Exeter Resource Corp.
GammaCan International, Inc.
Hartmarx Corporation
Helios & Matheson North America
INX, Inc.
Leading Brands, Inc.
Life Partners Holdings, Inc.
Lifeway Foods, Inc.
Littlefield Corporation
Manchester, Inc.
MFIC Corporation
Orchids Paper Products
Park City Group, Inc.
Pressure BioSciences, Inc.
QPC Lasers, Inc.
Radiant Logistics, Inc.
Reed's Inc.
Salon Media Group, Inc.
Simulations Plus, Inc.
TranSwitch Corporation
Triton Dist. Sys., Inc.
UFP Technologies, Inc.
US 1 Industries, Inc.
Wave Systems Corp.
Williams Controls, Inc.
|
|
